Get the Stockscreener App
6.99
3.05%
-0.22
Pre-market:
6.86
-0.13
-1.86%
Myriad Genetics Inc stock is traded at $6.99, with a volume of 953.39K.
It is down -3.05% in the last 24 hours and up +4.17% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$7.21
Open:
$7.29
24h Volume:
953.39K
Relative Volume:
0.83
Market Cap:
$651.56M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-5.3769
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-1.13%
1M Performance:
+4.17%
6M Performance:
+38.97%
1Y Performance:
-51.56%
1-Day Range:
$6.905
$7.32
1-Week Range:
$6.905
$7.43
52-Week Range:
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.99 | 672.07M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
575.91 | 215.01B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.53 | 159.87B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
700.55 | 56.23B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
140.60 | 39.54B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
223.63 | 37.85B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Published on: 2025-12-16 07:23:24 - earlytimes.in
Chart Watch: Why Myriad Genetics Inc stock could rally in 2025Weekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
Will Breakout in GIC Housing Finance Limited Sustain Through Next WeekCapital Gains Strategies & Free Unmatched Market Gains - earlytimes.in
Myriad Genetics, Inc. $MYGN Stake Reduced by Camber Capital Management LP - MarketBeat
Myriad Genetics Q3 2025 Earnings Preview - MSN
Discipline and Rules-Based Execution in MYGN Response - news.stocktradersdaily.com
Why Myriad Genetics (MYGN) Stock Is Up Today - Finviz
Myriad Genetics to Showcase Advances in Hereditary Cancer and MRD Testing at 2025 San Antonio Breast Cancer Symposium - Quiver Quantitative
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium - GlobeNewswire
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings? - TradingView
Prudential Financial Inc. Has $1.82 Million Stock Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Fisher Asset Management LLC Purchases 219,607 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
What MACD trends signal for Myriad Genetics Inc. (MYD) stock2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Why Myriad Genetics Inc. stock appeals to analystsWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Can Myriad Genetics Inc. stock continue upward trendMarket Trend Review & Low Drawdown Trading Techniques - Newser
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? - MSN
Upcoming Virtual Meeting on December 11 Hosted by Craig-Hallum f - GuruFocus
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial - GlobeNewswire Inc.
1 Healthcare Stock with Promising Prospects and 2 We Question - Barchart.com
How Myriad Genetics Inc. stock benefits from strong dollarTrade Risk Assessment & Low Drawdown Investment Ideas - Newser
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - Finviz
Myriad Genetics, Inc. $MYGN Stock Holdings Lifted by XTX Topco Ltd - MarketBeat
Myriad Genetics Outpaces Expectations But Faces Profit Challenges - Finimize
How Recent Developments Are Shaping the Myriad Genetics Investment Story - Yahoo Finance
UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral Recommendation - MSN
Will Myriad Genetics Inc. stock return to pre crisis levelsJuly 2025 Outlook & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Jaffetilchin Investment Partners LLC Buys New Shares in Myriad Genetics, Inc. $MYGN - MarketBeat
Will Myriad Genetics Inc. stock attract more institutional investorsPortfolio Growth Summary & Real-Time Buy Signal Notifications - BỘ NỘI VỤ
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
How Myriad Genetics achieved fast, accurate, and cost-efficient document processing using the AWS open-source Generative AI Intelligent Document Processing Accelerator - Amazon Web Services (AWS)
Earnings Recap: Can Myriad Genetics Inc. stock double in next 5 yearsTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know - MSN
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - The Manila Times
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools By Investing.com - Investing.com Nigeria
Myriad Genetics partners to use AI to measure breast cancer risk - Seeking Alpha
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools - Investing.com
Clairity, Myriad Genetics, and MagView Collaborate to Enhance Breast Cancer Risk Assessment Tool - Quiver Quantitative
Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - marketscreener.com
Myriad Genetics joins Forbes list of America's dream employers for 2026 - Traders Union
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):